Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.

Trial Profile

Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide; Glycopyranosyl lipid adjuvant
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Medicago
  • Most Recent Events

    • 24 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 20 Jun 2013 Interim data expected in the second half of 2013, according to a Medicago media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top